Abstract
The two indicated patents describe benzamide derivatives that are designed to inhibit p38 MAP kinase. This enzyme plays a key role in the biosynthesis of the pro-inflammatory cytokines TNF-α and IL-1. These patents report in vitro and ex vivo data for a small number of the compounds described therein.